ArticleCancer letters2020
VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.
Open access · greenAbstract read
In one paragraph
Article in Cancer letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Article
- Design and synthesis of novel 4-aryl-2-benzoyl-imidazoles as colchicine binding site inhibitors.European journal of medicinal chemistry · 2025Article
- Review
- Effect of PRKD3 on cell cycle in gastric cancer progression and downstream regulatory networks.Medical oncology (Northwood, London, England) · 2025Article
- JAK2/ULK1 axis promotes cervical cancer progression by autophagy induction and SRPK1 phosphorylation.Oncogene · 2025Article
- VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis.The Journal of pharmacology and experimental therapeutics · 2025Article
- Hippo signaling pathway in cervical cancer: insights into mechanisms and therapeutic potential.Frontiers in oncology · 2025Review
- Curcumin attenuates smoking and drinking activated NF-κB/IL-6 inflammatory signaling axis in cervical cancer.Cancer cell international · 2024Article
- BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.Science advances · 2024Article
- Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.Cancer letters · 2024Article
- Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.Current medicinal chemistry · 2024Review
- Review
- Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.Cell death discovery · 2022Article
- The prognostic value and biological significance of gap junction beta protein 2 (GJB2 or Cx26) in cervical cancer.Frontiers in oncology · 2022Article
- Predictive Study of the Active Ingredients and Potential Targets ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.Frontiers in pharmacology · 2021Article
- GJA1 Expression and Its Prognostic Value in Cervical Cancer.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Vivek K KashyapDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Nirnoy DanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Neeraj ChauhanDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Qinghui WangDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Saini SetuaDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Prashanth K B NageshDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Shabnam MalikDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Vivek BatraDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Murali M YallapuDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Duane D MillerDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Wei LiDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Bilal B HafeezDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Meena JaggiDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
Subhash C ChauhanDepartment of Immunology and Microbiology, The University of Texas Rio Grande Valley, McAllen, TX, 78504, USA; Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: subhash.chauhan@utrgv.edu.
University of Tennessee Health Science Center · USThe University of Texas Rio Grande Valley · US
Funding
Targeting the colchicine site in tubulin for advanced melanomaR01CA148706 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI, MILLER, DUANE D · 2011 to 2025
$5.3MMUC13 Mucin in Colorectal Cancer Health DisparityR01CA204552 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2020
$1.7MDevelopment of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7MTargeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7MEtiology of cervical cancer health disparity in American Indian womenU01CA162106 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CHAUHAN, SUBHASH C., JAGGI, MEENA · 2012 to 2016
$1.5MAcquisition of a Q-TOF Mass SpectrometerS10OD010678 · OD · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2012 to 2012
$325kAcquisition of a 400MHz Solution NMR System with an AutosamplerS10RR026377 · NCRR · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2010 to 2010
$253kNCI NIH HHS R01 CA148706NCI NIH HHS R01 CA204552NCI NIH HHS R01 CA206069NCI NIH HHS R01 CA210192NCI NIH HHS U01 CA162106NCRR NIH HHS S10 RR026377NIH HHS S10 OD010678
Abstract
In this study, we investigated the therapeutic efficacy of VERU-111 in vitro and in vivo model systems of cervical cancer. VERU-111 treatment inhibited cell proliferation and, clonogenic potential, induce accumulation of p53 and down regulated the expression of HPV E6/E7 expression in cervical cancer cells. In addition, VERU-111 treatment also decreased the phosphorylation of Jak2
Indexed as
AnimalsBenzimidazolesFemaleHeLa CellsHumansImidazolesIndolesJanus Kinase 2MicePapillomavirus E7 ProteinsPapillomavirus InfectionsPhosphorylationSignal TransductionSTAT3 Transcription FactorTumor Suppressor Protein p53Uterine Cervical NeoplasmsBenzimidazolesImidazolesIndolesJAK2 protein, humanJanus Kinase 2Papillomavirus E7 ProteinssabizabulinSTAT3 protein, humanSTAT3 Transcription FactorTP53 protein, humanTumor Suppressor Protein p53G2/M-phaseHPV16 E6/E7JAK2miR-23bSTAT3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.